|
Fractionated Stereotactic Radiotherapy vs. Single Session Radiosurgery in Patients With Larger Brain Metastases
RECRUITINGPhase 3Sponsored by University of Erlangen-Nürnberg Medical School
Actively Recruiting
PhasePhase 3
SponsorUniversity of Erlangen-Nürnberg Medical School
Started2021-05-18
Est. completion2026-05
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT03697343
Summary
Phase III trial comparing local control and side effects after fractionated stereotactic radiotherapy and single session radiosurgery in patients with larger brain metastases (2-4 cm)
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Age \> 18 years, no upper age limit * Karnofsky Performance Score \> 50 points * Expected Survival \> 3 months * 1-10 cerebral metastases of metastatic solid cancer * Indication for local radiotherapy * Patients must be able to understand the protocol and provide informed consent Exclusion Criteria: * Whole Brain radiotherapy no longer than 6 weeks before the start of stereotactic radiotherapy or planned whole brain radiotherapy after stereotactic radiotherapy * Prior irradiation of the cerebral metastasis that is to be treated in the study * Relevant overlap of prior radiation fields with the metastasis that is to be treated in the study * Metastasis in the brainstem * Contraindication for cerebral MRI * Metastasis that is to be treated in the study can't be visualized in contrast-enhanced T1 MRI sequence * Pregnant or lactating women * Abuse of illicit drugs, alcohol or medication * Patient not able or willing to behave according to protocol * Participation in another clinical trial
Conditions2
CancerCerebral Metastases of Solid Cancers
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 3
SponsorUniversity of Erlangen-Nürnberg Medical School
Started2021-05-18
Est. completion2026-05
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT03697343